Malaria vaccine - Mymetics

Drug Profile

Malaria vaccine - Mymetics

Alternative Names: PEV 1002A; PEV 301; PEV 302; PEV3; PEV3A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pevion Biotech
  • Developer Mymetics Corporation; Swiss Tropical Institute
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Malaria

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malaria in Switzerland (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malaria(In adolescents, In children) in Tanzania (Parenteral, Injection)
  • 05 Apr 2016 Data from a preclinical trial in Maleria released by Mymetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top